Institutional Investors Reshape Illumina Holdings as Norges Bank and Capital World Investors Boost Stakes
核心洞察
Norges Bank (搜索) acquired 540,134 shares of Illumina in Q4, a new position valued at approximately $70.8 million, representing 0.35% ownership.
Capital World Investors (搜索) increased its Illumina holdings by 0.6%, adding 124,323 shares to reach 20.1 million shares worth $2.64 billion.
Illumina reported Q1 earnings of $1.15 per share, beating consensus estimates by $0.10, with revenue of $1.09 billion up 4.8% year-over-year.
Norway's sovereign wealth fund, Norges Bank (搜索), has established a new position in Illumina, Inc. (NASDAQ: ILMN), purchasing 540,134 shares during the fourth quarter, according to a Form 13F filing with the Securities and Exchange Commission. The stake, valued at approximately $70.8 million, gives Norges Bank ownership of roughly 0.35% of the San Diego-based life sciences company.
Capital World Investors (搜索) also expanded its position in Illumina during the same period, growing its holdings by 0.6% with the acquisition of an additional 124,323 shares. The fund now holds 20,101,173 shares, representing 13.16% of the company and valued at $2.64 billion as of the most recent SEC filing.
These moves come amid broader institutional repositioning in Illumina. Empowered Funds LLC boosted its holdings by 113.7% in the first quarter, while Marshall Wace LLP increased its position by 49.0% in the second quarter. Overall, hedge funds and institutional investors now control 89.42% of Illumina's outstanding stock.
Financial Performance Exceeds Expectations
Illumina reported quarterly earnings on April 30, posting earnings per share of $1.15, which surpassed the consensus analyst estimate of $1.05 by $0.10. Revenue reached $1.09 billion for the quarter, exceeding analyst expectations of $1.07 billion and representing a 4.8% increase compared to the same period last year, when the company reported $0.97 EPS.
The company demonstrated strong profitability metrics, with a net margin of 19.42% and return on equity of 31.01%. Illumina has set its fiscal year 2026 earnings guidance at $5.15 to $5.30 per share, and analysts project earnings of $5.20 per share for the current year.
Analyst Community Maintains Cautious Stance
Despite the earnings beat, the analyst community remains measured in its outlook. Seven analysts have assigned a Buy rating to Illumina, while nine maintain a Hold rating and two recommend Sell. The consensus rating stands at "Hold" with an average price target of $138.38.
Recent analyst actions reflect divergent views. Royal Bank of Canada initiated coverage with an "Outperform" rating and a $170.00 price target on May 14. Daiwa Securities Group upgraded the stock from "Neutral" to "Outperform" with a $155.00 target. Conversely, Barclays raised its target from $110.00 to $122.00 while maintaining an "Underweight" rating, and Canaccord Genuity Group lowered its target from $150.00 to $140.00 with a "Hold" rating. Citigroup set a price objective of $95.00 with a "Sell" rating.
Insider Transactions and Market Position
Insider selling activity has been notable, with company insiders selling 1,002,371 shares valued at $155.5 million over the past quarter. Notable transactions include Director Keith A. Meister's sale of 235,000 shares at an average price of $163.63, totaling $38.5 million, and insider Scott M. Davies's sale of 615 shares at $160.00 per share. Insiders currently own 2.90% of the company's stock.
As of Friday's trading, Illumina shares opened at $162.32, with a 50-day moving average of $137.75 and a 200-day moving average of $133.57. The company's market capitalization stands at $24.56 billion, with a price-to-earnings ratio of 29.51 and a beta of 1.50. The stock has traded within a 52-week range of $82.44 to $177.22.
Illumina develops, manufactures, and markets integrated systems for genetic variation and function analysis, including next-generation sequencing platforms, microarrays for genotyping and methylation analysis, and library preparation kits. The company serves academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, and consumer genomics firms worldwide.